State of Michigan Retirement System 13F: Cuts TWST Stake by $16M

On October 27, 2026, the State of Michigan Retirement System cut its position in Twist Bioscience Corporation (TWST) by 81,472 shares, leaving it with 95,929 shares valued at about $18.5 million. This information comes from the fund's latest Form 13F filing with the SEC.

TWST Twist Bioscience Corporation

$159.85 ▲ +393.52% year to date

1M 3M YTD

Daily close · Oct 27, 2026

What Changed in State of Michigan Retirement System's Twist Bioscience Position

The State of Michigan Retirement System reduced its stake in Twist Bioscience by 81,472 shares, a decrease of 45.9%. The fund's reported value for this position is approximately $18.5 million.

Where Twist Bioscience Fits in State of Michigan Retirement System's Portfolio

Twist Bioscience now makes up 0.17% of the State of Michigan Retirement System's total reported portfolio, ranking 37 out of 966 positions.

Other Institutional Activity in Twist Bioscience

Artisan Partners Limited Partnership cut its holdings by 1,565,861 shares, ending with 4,802,017 shares valued at about $767.6 million. Similarly, ARK Investment Management reduced its position by 1,793,154 shares, now holding 4,549,803 shares worth approximately $727.3 million. Edgepoint Investment Group also decreased its stake by 2,860,724 shares, resulting in 2,521,635 shares valued at about $403.1 million.

Twist Bioscience Corporation Stock Up 10.1%

Twist Bioscience recently traded around $159.85, which is about equal to its closing price on the filing date. The stock is currently above its 50-day moving average by 6.4% and well above its 52-week low, but it remains below its 52-week high by 27.2%.

Recent Earnings

Twist Bioscience reported trailing twelve-month revenue of approximately $431.8 million, with a negative net margin of 31.7%. The company is expected to announce its next earnings report on November 12, 2026.

Insider Buying and Selling at Twist Bioscience Corporation

Several insiders sold shares recently. Paula Green, an officer, sold 10,088 shares at an average price of $188.88 on October 2, 2026, totaling approximately $1.9 million. Robert F. Werner, another officer, sold 1,482 shares for about $279,926. Chief Executive Officer Emily M. Leproust sold 4,548 shares, valued at approximately $919,374, while Chief Financial Officer Adam Laponis sold 2,462 shares at an average price of $156.30, totaling about $384,823.

Analysts Set New Price Targets

On October 1, 2026, Guggenheim maintained a Buy rating on Twist Bioscience with a price target of $212. Later, Barclays also maintained an Overweight rating with a target of $215 on October 7, 2026. The consensus recommendation for the stock is a Buy, with a mean price target of $168.25 based on 12 analyst opinions.

About Twist Bioscience

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company's technology is used across various sectors, including healthcare and biotechnology, making it a key player in the synthetic biology field.

Bottom Line

Investors will be watching for Twist Bioscience's upcoming earnings report on November 12, 2026. Additionally, keep an eye on further filings from the State of Michigan Retirement System and other institutional investors regarding their positions in the company.